FDA and Health Canada approval of INQOVI® (decitabine and cedazuridine) tablets, oral hypomethylating agent (HMA) therapy for intermediate and high-risk MDS and CMML - Guillermo Garcia-M...

FDA and Health Canada approval of INQOVI® (decitabine and cedazuridine) tablets, oral hypomethylating agent (HMA) therapy for intermediate and high-risk MDS and CMML - Guillermo Garcia-M...

User Photo
Cancer-News

2 months
50 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Guillermo Garcia-Manero, MD - MD Anderson Cancer Center discusses Astex Pharmaceuticals, Taiho Oncology, and Otsuka Pharmaceutical announce FDA and Health Canada approval of INQOVI® (decitabine and cedazuridine) tablets, oral hypomethylating agent (HMA) therapy for intermediate and high-risk MDS and CMML


https://astx.com/astex-pharmaceuticals-taiho-oncology-and-otsuka-pharmaceutical-announce-fda-and-health-canada-approval-of-inqovi-decitabine-and-cedazuridine-tablets-oral-hypomethylating-agent-hma-therapy/
Up Next Autoplay
>